<DOC>
	<DOCNO>NCT01788995</DOCNO>
	<brief_summary>This non-interventional study evaluate routine use safety efficacy Avastin ( bevacizumab ) first-line treatment patient advanced ovarian cancer ( epithelial ovarian cancer , fallopian tube carcinoma , primary peritoneal carcinoma ) . Newly diagnose patient initiated carboplatin/paclitaxel chemotherapy combination Avastin follow 15 month treatment 12 month follow-up .</brief_summary>
	<brief_title>BOVARI : A Non-Interventional Study Avastin ( Bevacizumab ) Front-Line Treatment Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients newly diagnose advanced epithelial ovarian cancer ( EOC ) , fallopian tube carcinoma ( FTC ) primary peritoneal carcinoma ( PPC ) indication firstline carboplatin/paclitaxel chemotherapy combination Avastin Contraindications Avastin accord Summary Product Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>